INTENDED FOR UK AND IRELAND HEALTHCARE PROFESSIONALS HomePrescribing information

Bramitob® offers a favourable safety profile

  • 98% adherence rates across Phase II/III clinical trials1,2
  • In a placebo-controlled trial, generally well-tolerated, with a low incidence of hearing disturbance and bronchospasm1

 

REPORTED ADVERSE EVENTS3*

 


*Data derived from 4 controlled clinical trials and 1 uncontrolled clinical trial with Bramitob, n=565
Common (≥1/100 and <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 and <1000); very rare (<1/10,000)

For the full list of Adverse Events, please see the UK Summary of Product Characteristics or the Ireland Summary of Product Characteristics.

HIGH RATES OF ADHERENCE ACROSS CLINICAL TRIALS1,2